Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical study evaluating MVP-S and DPX-SurMAGE, CPA and anti-PD-1 for the treatment of muscle invasive bladder cancer prior and after cystectomy

Next Previous
Trial Profile

A phase I clinical study evaluating MVP-S and DPX-SurMAGE, CPA and anti-PD-1 for the treatment of muscle invasive bladder cancer prior and after cystectomy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 16 Mar 2023 According to an IMV media release, preliminary data from this study in Q3 2023.
  • 11 Aug 2022 According to an IMV media release, first patient dosing with DPX-SurMAGE in second arm expected in Q3 2022, and Initial data on DPX-SurMAGE arm expected in H1 2023.
  • 13 May 2022 According to a IMV media release, the first patient was dosed early April 2022. Early data look expected in Q4 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top